449 related articles for article (PubMed ID: 28067895)
21. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H
J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909
[TBL] [Abstract][Full Text] [Related]
22. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
23. Neurofibromin (NF1) genetic variant structure-function analyses using a full-length mouse cDNA.
Wallis D; Li K; Lui H; Hu K; Chen MJ; Li J; Kang J; Das S; Korf BR; Kesterson RA
Hum Mutat; 2018 Jun; 39(6):816-821. PubMed ID: 29522274
[TBL] [Abstract][Full Text] [Related]
24. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
[TBL] [Abstract][Full Text] [Related]
25. RAS and beyond: the many faces of the neurofibromatosis type 1 protein.
Anastasaki C; Orozco P; Gutmann DH
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35188187
[TBL] [Abstract][Full Text] [Related]
26. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
27. Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?
Fareez F; Wang BH; Brain I; Lu JQ
Pathology; 2023 Apr; 55(3):302-314. PubMed ID: 36774237
[TBL] [Abstract][Full Text] [Related]
28. A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1.
Esposito T; Piluso G; Saracino D; Uccello R; Schettino C; Dato C; Capaldo G; Giugliano T; Varriale B; Paolisso G; Di Iorio G; Melone MA
J Neurochem; 2015 Dec; 135(6):1123-8. PubMed ID: 26478990
[TBL] [Abstract][Full Text] [Related]
29. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
30. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
31. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.
Anastasaki C; Woo AS; Messiaen LM; Gutmann DH
Hum Mol Genet; 2015 Jun; 24(12):3518-28. PubMed ID: 25788518
[TBL] [Abstract][Full Text] [Related]
32. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes.
Dasgupta B; Dugan LL; Gutmann DH
J Neurosci; 2003 Oct; 23(26):8949-54. PubMed ID: 14523097
[TBL] [Abstract][Full Text] [Related]
33. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
[TBL] [Abstract][Full Text] [Related]
35. Molecular Markers and Targets in Melanoma.
Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
[TBL] [Abstract][Full Text] [Related]
36. NF1 Mutations Prevalent but Not Clinically Relevant.
Cancer Discov; 2015 Oct; 5(10):OF1. PubMed ID: 26283687
[TBL] [Abstract][Full Text] [Related]
37. A novel mutation in NF1 gene of patient with Neurofibromatosis type 1: A case report and functional study.
Zhang T; Jia C; Dong Z; Li C; Lu W
Mol Genet Genomic Med; 2021 May; 9(5):e1643. PubMed ID: 33764694
[TBL] [Abstract][Full Text] [Related]
38. Somatic mutations in the neurofibromatosis 1 gene in human tumors.
Li Y; Bollag G; Clark R; Stevens J; Conroy L; Fults D; Ward K; Friedman E; Samowitz W; Robertson M
Cell; 1992 Apr; 69(2):275-81. PubMed ID: 1568247
[TBL] [Abstract][Full Text] [Related]
39. [Neurofibromin - protein structure and cellular functions in the context of neurofibromatosis type I pathogenesis].
Abramowicz A; Gos M
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1331-48. PubMed ID: 26671924
[TBL] [Abstract][Full Text] [Related]
40. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
Brems H; Legius E
Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
